Skip to main content
. 2016 Sep 6;34(32):3921–3930. doi: 10.1200/JCO.2016.66.9648

Fig A1.

Fig A1.

Mean European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) domain scores over time, stratified by the time of last assessment. Pattern 1 shows mean scores at each visit for patients with a GHS/QoL score at all visits to cycle 18. Pattern 2 shows mean scores for patients with GHS/QoL scores up to cycle 12. Pattern 3 shows mean scores for patients with GHS/QoL scores up to cycle 6. Pattern 4 shows mean scores for patients with GHS/QoL scores up to cycle 3. Pattern 5 shows mean scores for patients with baseline GHS/QoL scores only. Graphs do not contain intermittent missing patterns. Percentages are based on the total number of patients in the carfilzomib, lenalidomide, and dexamethasone (KRd; n = 396) and lenalidomide and dexamethasone (Rd; n = 396) treatment groups.